Joseph Chiesa

Phase I First-in-Humans Trial of ALN-TTRsc, a Novel RNA Interference Therapeutic for the Treatment of Familial Amyloidotic Cardiomyopathy (FAC)

Tracy S. Zimmermann, J. Gollob, R. Falzone, 2013 .

Abstract 67: Phase I Safety, Pharmacokinetic, and Pharmacodynamic Results for ALN-PCS, a Novel RNAi Therapeutic for the Treatment of Hypercholesterolemia

J. Ritter, L. Nechev, K. Fitzgerald, 2012, Arteriosclerosis, Thrombosis, and Vascular Biology.

Clinical Proof of Concept for a Novel Hepatocyte-Targeting GalNAc-siRNA Conjugate.

B. Bettencourt, Tracy S. Zimmermann, J. Gollob, 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

Safety and efficacy of RNAi therapy for transthyretin amyloidosis.

B. Bettencourt, P. Lozeron, P. Hawkins, 2013, The New England journal of medicine.

Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial

B. Bettencourt, Svetlana Shulga-Morskaya, J. Gollob, 2014, The Lancet.

A phase 1 study to evaluate the safety and pharmacokinetics of PQ912, a glutaminyl cyclase inhibitor, in healthy subjects

F. Weber, T. Hoffmann, U. Heiser, 2015, Alzheimer's & dementia.

Safety, pharmacokinetics, pharmacogenomics and QT concentration-effect modelling of the SirT1 inhibitor selisistat in healthy volunteers.

D. Diamanti, G. Pollio, B. Darpo, 2015, British journal of clinical pharmacology.

Pharmacokinetics of Intravenous Finafloxacin in Healthy Volunteers

U. Fuhr, Joseph Chiesa, A. Dalhoff, 2017, Antimicrobial Agents and Chemotherapy.

Clinical Proof of Concept for a Novel Hepatocyte-Targeting GalNAc-siRNA Conjugate.

B. Bettencourt, Tracy S. Zimmermann, J. Gollob, 2017, Molecular therapy : the journal of the American Society of Gene Therapy.